– SWITZERLAND, Schlieren – LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors, bringing over 30 years of senior executive and board-level experience in the life science and healthcare industries. He succeeds Dr. Philippe Dro who will remain on the Board of Directors representing Adjuvant Capital.
About Staph Leavenworth Bakali
Staph Leavenworth Bakali has led early-stage and mature companies through product development, growth, and commercialization while raising significant capital and has been closely involved in several successful exits.
Staph Leavenworth Bakali commented, “As antimicrobial resistance continues to rise globally, infections will become increasingly difficult or impossible to treat. LimmaTech is at the forefront of combating this epidemic with a robust pipeline of vaccine candidates that can mitigate this escalating risk and control several highly transmissible pathogens. I look forward to sharing my experience and working with the LimmaTech team in our mission to address significant global medical needs and making a meaningful impact on people’s lives.”
Staph Leavenworth Bakali most recently served as CEO and President of George Health Enterprises, the commercial arm of The George Institute for Global Health, a leading medical research institute. In this role, he was deeply involved in establishing and growing a portfolio of companies focused on providing market-disruptive treatments, technologies, devices, and services addressing the large and fast-growing global chronic disease market. Previously, he served as President and COO at the Clinton Health Access Initiative, a non-profit organization founded by former U.S. President Bill Clinton. He held several senior leadership roles in the vaccine industry, including CEO and Director of vaccine development companies Genocea Biosciences and Intercell, respectively. He served as COO at ID Biomedical and PowderJect Pharmaceuticals, which were acquired by GlaxoSmithKline and Chiron, respectively. He served as the Global Commercial Head of Sales for Chiron’s global vaccine business and the Director of SmithKline Beecham’s vaccine business unit in France.
Staph Leavenworth Bakali holds a Master’s in Management from the London Business School.
About LimmaTech Biologics
LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide.
LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund, and Tenmile.
For more information: https://lmtbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.